Boehringer Ingelheim, the world's largest private pharmaceutical company, was hit with an antitrust class action lawsuit alleging that the company is using expired patents to delay competition between brand name and generic inhalers.

The lawsuit, filed last month in Connecticut federal court, was followed by the Federal Trade Commission's announcement that it sent warning letters to 10 companies, including Boehringer Ingelheim, disputing the "accuracy or relevance" of patent listings in the Food and Drug Administration's Orange Book.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Emily Cousins

I'm a litigation reporter for Connecticut Law Tribune, covering litigation wins, verdict news, settlements, interesting cases, etc. Contact me with tips at [email protected].